Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Invest New Drugs
; 41(3): 391-401, 2023 Jun.
Article
in En
| MEDLINE
| ID: mdl-37043123
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Triple Negative Breast Neoplasms
Limits:
Female
/
Humans
Language:
En
Journal:
Invest New Drugs
Year:
2023
Document type:
Article
Affiliation country: